Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000932440-12-000300
Filing Date
2012-12-28
Accepted
2012-12-28 16:44:32
Documents
2
Group Members
RIDGEBACK CAPITAL INVESTMENTS LTD.RIDGEBACK CAPITAL MANAGEMENT LP

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G sch13g_1682431.htm SC 13G 160186
2 JOINT FILING AGREEMENT exh99-1_1682433.htm EX-99.1 13948
  Complete submission text file 0000932440-12-000300.txt   175913
Mailing Address 119 FOURTH AVE NEEDHAM MA 02494-2725
Business Address 119 FOURTH AVE NEEDHAM MA 02494 7814330771
Celldex Therapeutics, Inc. (Subject) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-37761 | Film No.: 121291402
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 430 PARK AVENUE 12TH FLOOR NEW YORK NY 10022
Business Address 430 PARK AVENUE 12TH FLOOR NEW YORK NY 10022 212-624-2567
Ridgeback Capital Investments L.P. (Filed by) CIK: 0001423994 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G